Feb 27 |
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
|
Feb 5 |
Verrica sues to keep unapproved cantharidin drugs off US market
|
Feb 5 |
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
|
Jan 29 |
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
|
Jan 23 |
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
|
Jan 6 |
Verrica Pharmaceuticals: There Is A Silver Lining With YCANTH's Commercialization
|
Jan 5 |
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
|
Jan 4 |
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
|
Jan 3 |
Verrica Pharmaceuticals stock gains on Walgreens distribution deal
|
Jan 3 |
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
|